PMC:7534795 / 104520-105999 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":414,"end":422},"obj":"Body_part"},{"id":"T35","span":{"begin":1004,"end":1009},"obj":"Body_part"},{"id":"T36","span":{"begin":1078,"end":1083},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T137","span":{"begin":1004,"end":1009},"obj":"Body_part"},{"id":"T138","span":{"begin":1078,"end":1083},"obj":"Body_part"}],"attributes":[{"id":"A137","pred":"uberon_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A138","pred":"uberon_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T575","span":{"begin":127,"end":135},"obj":"Disease"},{"id":"T576","span":{"begin":264,"end":272},"obj":"Disease"},{"id":"T577","span":{"begin":457,"end":465},"obj":"Disease"},{"id":"T578","span":{"begin":476,"end":482},"obj":"Disease"},{"id":"T579","span":{"begin":576,"end":584},"obj":"Disease"},{"id":"T580","span":{"begin":599,"end":611},"obj":"Disease"},{"id":"T581","span":{"begin":682,"end":690},"obj":"Disease"},{"id":"T582","span":{"begin":894,"end":902},"obj":"Disease"},{"id":"T583","span":{"begin":1023,"end":1026},"obj":"Disease"},{"id":"T584","span":{"begin":1078,"end":1091},"obj":"Disease"},{"id":"T585","span":{"begin":1308,"end":1316},"obj":"Disease"},{"id":"T586","span":{"begin":1319,"end":1328},"obj":"Disease"},{"id":"T587","span":{"begin":1461,"end":1469},"obj":"Disease"}],"attributes":[{"id":"A575","pred":"mondo_id","subj":"T575","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A576","pred":"mondo_id","subj":"T576","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A577","pred":"mondo_id","subj":"T577","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A578","pred":"mondo_id","subj":"T578","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A579","pred":"mondo_id","subj":"T579","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A580","pred":"mondo_id","subj":"T580","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A581","pred":"mondo_id","subj":"T581","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A582","pred":"mondo_id","subj":"T582","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A583","pred":"mondo_id","subj":"T583","obj":"http://purl.obolibrary.org/obo/MONDO_0020108"},{"id":"A584","pred":"mondo_id","subj":"T584","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A585","pred":"mondo_id","subj":"T585","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A586","pred":"mondo_id","subj":"T586","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A587","pred":"mondo_id","subj":"T587","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T55","span":{"begin":62,"end":70},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T56","span":{"begin":412,"end":413},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T57","span":{"begin":490,"end":492},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T58","span":{"begin":490,"end":492},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T59","span":{"begin":522,"end":523},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T60","span":{"begin":970,"end":971},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T61","span":{"begin":1004,"end":1009},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T62","span":{"begin":1004,"end":1009},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T63","span":{"begin":1004,"end":1009},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T64","span":{"begin":1004,"end":1009},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T65","span":{"begin":1078,"end":1083},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T66","span":{"begin":1078,"end":1083},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T67","span":{"begin":1078,"end":1083},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T68","span":{"begin":1078,"end":1083},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T69","span":{"begin":1343,"end":1344},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T8642","span":{"begin":214,"end":228},"obj":"Chemical"},{"id":"T64765","span":{"begin":218,"end":228},"obj":"Chemical"},{"id":"T98256","span":{"begin":490,"end":492},"obj":"Chemical"},{"id":"T99","span":{"begin":618,"end":632},"obj":"Chemical"},{"id":"T58213","span":{"begin":622,"end":632},"obj":"Chemical"},{"id":"T47825","span":{"begin":717,"end":731},"obj":"Chemical"},{"id":"T12352","span":{"begin":721,"end":731},"obj":"Chemical"},{"id":"T22206","span":{"begin":843,"end":852},"obj":"Chemical"},{"id":"T31919","span":{"begin":1023,"end":1026},"obj":"Chemical"},{"id":"T30574","span":{"begin":1065,"end":1068},"obj":"Chemical"},{"id":"T36552","span":{"begin":1148,"end":1161},"obj":"Chemical"},{"id":"T48816","span":{"begin":1152,"end":1161},"obj":"Chemical"},{"id":"T31232","span":{"begin":1261,"end":1263},"obj":"Chemical"}],"attributes":[{"id":"A97433","pred":"chebi_id","subj":"T8642","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A60807","pred":"chebi_id","subj":"T64765","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A33291","pred":"chebi_id","subj":"T98256","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"},{"id":"A24233","pred":"chebi_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A28836","pred":"chebi_id","subj":"T58213","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A11208","pred":"chebi_id","subj":"T47825","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A52250","pred":"chebi_id","subj":"T12352","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A20344","pred":"chebi_id","subj":"T22206","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A90463","pred":"chebi_id","subj":"T31919","obj":"http://purl.obolibrary.org/obo/CHEBI_27777"},{"id":"A78804","pred":"chebi_id","subj":"T30574","obj":"http://purl.obolibrary.org/obo/CHEBI_18053"},{"id":"A13120","pred":"chebi_id","subj":"T30574","obj":"http://purl.obolibrary.org/obo/CHEBI_30526"},{"id":"A21473","pred":"chebi_id","subj":"T36552","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A10979","pred":"chebi_id","subj":"T48816","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A96639","pred":"chebi_id","subj":"T31232","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T13","span":{"begin":1368,"end":1389},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T14","span":{"begin":1394,"end":1410},"obj":"http://purl.obolibrary.org/obo/GO_0042310"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T652","span":{"begin":0,"end":169},"obj":"Sentence"},{"id":"T653","span":{"begin":170,"end":316},"obj":"Sentence"},{"id":"T654","span":{"begin":317,"end":521},"obj":"Sentence"},{"id":"T655","span":{"begin":522,"end":757},"obj":"Sentence"},{"id":"T656","span":{"begin":758,"end":954},"obj":"Sentence"},{"id":"T657","span":{"begin":955,"end":1199},"obj":"Sentence"},{"id":"T658","span":{"begin":1200,"end":1479},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T234","span":{"begin":414,"end":428},"obj":"Phenotype"},{"id":"T235","span":{"begin":599,"end":611},"obj":"Phenotype"},{"id":"T236","span":{"begin":1078,"end":1091},"obj":"Phenotype"}],"attributes":[{"id":"A234","pred":"hp_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A235","pred":"hp_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A236","pred":"hp_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/HP_0001635"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"2_test","denotations":[{"id":"33031856-32228252-84039124","span":{"begin":163,"end":167},"obj":"32228252"},{"id":"33031856-32195824-84039125","span":{"begin":310,"end":314},"obj":"32195824"},{"id":"33031856-32227090-84039126","span":{"begin":515,"end":519},"obj":"32227090"},{"id":"33031856-32348166-84039127","span":{"begin":751,"end":755},"obj":"32348166"},{"id":"33031856-32356627-84039128","span":{"begin":948,"end":952},"obj":"32356627"},{"id":"33031856-32302265-84039129","span":{"begin":1193,"end":1197},"obj":"32302265"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2956","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"2957","span":{"begin":214,"end":217},"obj":"Gene"},{"id":"2958","span":{"begin":371,"end":375},"obj":"Gene"},{"id":"2959","span":{"begin":618,"end":621},"obj":"Gene"},{"id":"2960","span":{"begin":717,"end":720},"obj":"Gene"},{"id":"2961","span":{"begin":1148,"end":1151},"obj":"Gene"},{"id":"2962","span":{"begin":1249,"end":1252},"obj":"Gene"},{"id":"2963","span":{"begin":127,"end":137},"obj":"Species"},{"id":"2964","span":{"begin":273,"end":281},"obj":"Species"},{"id":"2965","span":{"begin":457,"end":467},"obj":"Species"},{"id":"2966","span":{"begin":585,"end":593},"obj":"Species"},{"id":"2967","span":{"begin":691,"end":699},"obj":"Species"},{"id":"2968","span":{"begin":796,"end":804},"obj":"Species"},{"id":"2969","span":{"begin":1470,"end":1478},"obj":"Species"},{"id":"2970","span":{"begin":264,"end":272},"obj":"Disease"},{"id":"2971","span":{"begin":576,"end":584},"obj":"Disease"},{"id":"2972","span":{"begin":599,"end":611},"obj":"Disease"},{"id":"2973","span":{"begin":648,"end":657},"obj":"Disease"},{"id":"2974","span":{"begin":669,"end":681},"obj":"Disease"},{"id":"2975","span":{"begin":682,"end":690},"obj":"Disease"},{"id":"2976","span":{"begin":894,"end":902},"obj":"Disease"},{"id":"2977","span":{"begin":1023,"end":1026},"obj":"Disease"},{"id":"2978","span":{"begin":1308,"end":1328},"obj":"Disease"},{"id":"2979","span":{"begin":1461,"end":1469},"obj":"Disease"}],"attributes":[{"id":"A2956","pred":"tao:has_database_id","subj":"2956","obj":"Gene:59272"},{"id":"A2957","pred":"tao:has_database_id","subj":"2957","obj":"Gene:1636"},{"id":"A2958","pred":"tao:has_database_id","subj":"2958","obj":"Gene:59272"},{"id":"A2959","pred":"tao:has_database_id","subj":"2959","obj":"Gene:1636"},{"id":"A2960","pred":"tao:has_database_id","subj":"2960","obj":"Gene:1636"},{"id":"A2961","pred":"tao:has_database_id","subj":"2961","obj":"Gene:1636"},{"id":"A2962","pred":"tao:has_database_id","subj":"2962","obj":"Gene:1636"},{"id":"A2963","pred":"tao:has_database_id","subj":"2963","obj":"Tax:2697049"},{"id":"A2964","pred":"tao:has_database_id","subj":"2964","obj":"Tax:9606"},{"id":"A2965","pred":"tao:has_database_id","subj":"2965","obj":"Tax:2697049"},{"id":"A2966","pred":"tao:has_database_id","subj":"2966","obj":"Tax:9606"},{"id":"A2967","pred":"tao:has_database_id","subj":"2967","obj":"Tax:9606"},{"id":"A2968","pred":"tao:has_database_id","subj":"2968","obj":"Tax:9606"},{"id":"A2969","pred":"tao:has_database_id","subj":"2969","obj":"Tax:9606"},{"id":"A2970","pred":"tao:has_database_id","subj":"2970","obj":"MESH:C000657245"},{"id":"A2971","pred":"tao:has_database_id","subj":"2971","obj":"MESH:C000657245"},{"id":"A2972","pred":"tao:has_database_id","subj":"2972","obj":"MESH:D006973"},{"id":"A2973","pred":"tao:has_database_id","subj":"2973","obj":"MESH:D003643"},{"id":"A2974","pred":"tao:has_database_id","subj":"2974","obj":"MESH:D006973"},{"id":"A2975","pred":"tao:has_database_id","subj":"2975","obj":"MESH:C000657245"},{"id":"A2976","pred":"tao:has_database_id","subj":"2976","obj":"MESH:C000657245"},{"id":"A2978","pred":"tao:has_database_id","subj":"2978","obj":"MESH:C000657245"},{"id":"A2979","pred":"tao:has_database_id","subj":"2979","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Importantly, evidence demonstrating upregulation and enhanced activity of ACE2 suggested it will facilitate the infectivity of SARS-CoV-2 (South, Diz, \u0026 Chappell, 2020). Accordingly, some researchers proposed that ACE inhibitors and ARBs should be discontinued in COVID-19 patients (Diaz, 2020; Esler \u0026 Esler, 2020). However, in addition to the direct effects on cardiac ACE2 other mechanisms such as triggering a cytokine storm will markedly contribute to SARS-CoV-2-induced injury (Chen, Li, Chen, Feng, \u0026 Xiong, 2020). A recent study conducted by Yang et al., demonstrated COVID-19 patients with hypertension using ACE inhibitors/ARBs had lower mortality rates than hypertensive COVID-19 patients that were not on ACE inhibitors/ARBs (Yang et al., 2020). Moreover, Mancia et al. examined 6272 patients and found no association between RAAS inhibitor use and susceptibility or development of COVID-19 (Mancia, Rea, Ludergnani, Apolone, \u0026 Corrao, 2020). In that sense, a published statement by American Heart Association (AHA), the American College of Cardiology (ACC) and the Heart Failure Society of America strongly recommended continuation of ACE inhibitor/ARBs (Zhang, Zhu, Cai, et al., 2020). Together, these data suggest therapies targeting ACE and Ang II do not appear to increase the likelihood of SARS-CoV-2 infection, but may have a role in abrogating the inflammatory response and vasoconstriction that contributes to the clinical deterioration in COVID-19 patients."}